The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Esomeprazole; Fluoroquinolones; Metronidazole; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Tetracycline

Criteria

Inclusion Criteria:

• The patients who proved H. pylori infection following three methods

1. positive rapid urease test (CLOtest)

2. histologic evidence of H. pylori by modified Giemsa staining

3. positive Urea breath test

• Male and female Korean Adult (Aged ≥ 18 years)

Exclusion Criteria:

• Patients who received eradication therapy for H. pylori infection, previously

• H. pylori eradication failure because of poor compliance

• the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks

• Advanced gastric cancer or other malignancy

• Abnormal liver function or liver cirrhosis

• Abnormal renal function or chronic kidney disease

• Other severe concurrent diseases

• Previous allergic reactions to the study drugs

• Pregnant or lactating women